Jakarta, CNN Indonesia –
Deputy Minister BUMN I as well as Chair of the National Economic Recovery Task Force (PEN) Budi Gunadi Sadikin said the government on Monday (7/12) has stated its commitment to Gavi as one of the providers covid-19 vaccine.
To note, Gavi is a coalition of world countries committed to providing a covid-19 vaccine. Countries that are joined will receive the covid-19 vaccine as much as 20 percent of the country’s population.
The coalition, which is still under WHO, is a facilitator of the pillar of access to the Covid-19 vaccine made by Covax.
“Under the leadership and coordination of the Ministry of Health, today the Indonesian government has confirmed to Gavi as one of the vaccine providers under WHO coordination to participate in opening access for 20 percent of Indonesia’s target population to be able to get vaccines at a good price,” he said to video conference, Monday (7/12).
He said this commitment was one of the ways for the government to ensure that all Indonesians could get access to the covid-19 vaccine.
On the same occasion, he also revealed that this month, 1.8 million doses of the covid-19 vaccine will come. If the total is 1.2 million doses of the vaccine that arrived earlier on Sunday (6/12), the total vaccine that will arrive at the end of 2020 is 3 million doses.
In addition to the finished vaccine, he said that Indonesia would also receive 15 million doses of the Covid-19 vaccine raw material, which would then be processed by Bio Farma into 12 million doses of vaccine. This new vaccine will be available early next year.
After that, in January 2020, an additional 30 million doses of vaccine raw materials will arrive, which will be processed into a vaccine to become 24 million doses. It is estimated that the new vaccine will be ready a month later or in February.
However, he did not specify where the vaccines came from.
Even so, he reminded that the vaccination program could only be carried out after a series of in-depth scientific studies by BPOM.
Before vaccines can be injected, he urged the public to remain disciplined in implementing health protocols such as 3M or washing hands, maintaining distance, and wearing masks.
In addition, the 3 T practice, namely tracing, testing, dan treatment.
Disclaimer: Until now, there are no known data on the safety and efficacy (efficacy) of the third phase clinical trial of the Sinovac vaccine. This is different from Pfizer, which has issued efficacy data, which is 90 percent effective, and Moderna, which claims an effectiveness level of up to 94.5 percent.
In Indonesia, the clinical trial of the Sinovac Vaccine in collaboration with Bio Farma and Padjadjaran University will only be completed in May 2021 and the initial report is in January 2021.
(well / eight)
– .
